Abstract

Dimerization of G protein-coupled receptors (GPCRs) is crucial for receptor function including agonist affinity, efficacy, trafficking and specificity of signal transduction, including G protein coupling. Emerging data suggest that the cardiovascular system is the main target of apelin, which exerts an overall neuroprotective role, and is a positive regulator of angiotensin-converting enzyme 2 (ACE2) in heart failure. Moreover, ACE2 cleaves off C-terminal residues of vasoactive peptides including apelin-13, and neurotensin that activate the apelin receptor (APJ) and neurotensin receptor 1 (NTSR1) respectively, that belong to the A class of GPCRs. Therefore, based on the similar mode of modification by ACE2 at peptide level, the homology at amino acid level and the capability of forming dimers with other GPCRs, we have been suggested that APJ and NTSR1 can form a functional heterodimer. Using co-immunoprecipitation, BRET and FRET, we provided conclusive evidence of heterodimerization between APJ and NTSR1 in a constitutive and induced form. Upon agonist stimulation, hetrodimerization enhanced ERK1/2 activation and increased proliferation via activation of Gq α-subunits. These novel data provide evidence for a physiological role of APJ/NTSR1 heterodimers in terms of ERK1/2 activation and increased intracellular calcium and induced cell proliferation and provide potential new pharmaceutical targets for cardiovascular disease.

Highlights

  • Apelin is an adipokine that exerts pleiotropic effects on the cardiovascular system

  • angiotensin-converting enzyme 2 (ACE2) is a negative regulator of the reninangiotensin system (RAS), since it catalyses the conversion of angiotensin II (Ang II) to angiotensin 1-7 (Ang1-7) [2]

  • These data demonstrate that activation of APJ/ neurotensin receptor 1 (NTSR1) heterodimers could increase Human Embryonic Kidney 293 (HEK293) cell proliferation

Read more

Summary

Introduction

Apelin is an adipokine that exerts pleiotropic effects on the cardiovascular system. Emerging data have suggested that apelin is a positive regulator of angiotensin-converting enzyme 2 (ACE2) in heart failure in vivo [1]. ACE2 is a negative regulator of the reninangiotensin system (RAS), since it catalyses the conversion of angiotensin II (Ang II) to angiotensin 1-7 (Ang1-7) [2]. Apelin is a Apelin exerts its affects by binding and activating the apelin receptor (APJ, gene symbol APLNR), a member of the GPCR super-family. APJ is capable of binding a number of apelin isoforms, activate different classes of G protein a-subunits and subsequently induce several signalling pathways in cell- and tissue-specific manner [2, 6]. ACE2 removed the C-terminal residue from the a 2014 The Authors

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call